[1]
Neelam, A. and Kanaki, A. 2021. Efficacy and safety of remogliflozin etabonate in type 2 diabetes mellitus patients in a tertiary care hospital. International Journal of Basic & Clinical Pharmacology. 10, 4 (Mar. 2021), 353–356. DOI:https://doi.org/10.18203/2319-2003.ijbcp20211014.